JOINT FILING AGREEMENTJoint Filing Agreement • February 27th, 2023 • Velan Capital Investment Management LP • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Voting Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • March 15th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations • New York
This Joint Filing and Solicitation Agreement (this “Agreement”) is made and entered into as of March 11, 2022, by and among (i) Velan Capital Partners LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Avego Management, LLC and Balaji Venkataraman (collectively, “Velan”), (ii) Repertoire Master Fund LP, Repertoire Holdings LLC, Repertoire Partners LP, Repertoire Partners GP LLC and Deepak Sarpangal (collectively, “Repertoire”), (iii) Eric J. Ende, (iv) R. John Fletcher, (v) Cynthia L. Flowers and (vi) Ann MacDougall (each a “Party” to this Agreement, and collectively, the “Parties” or the “Group”).
Joint Filing AgreementJoint Filing Agreement • January 27th, 2023 • Velan Capital Investment Management LP • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on Schedule 13G dated January 27, 2023 with respect to the Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • July 12th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.0001 per share, of Radius Health, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
AMENDMENT AND JOINDER TO JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • April 18th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations
This Amendment and Joinder (this “Amendment”) is made and entered into as of April 18, 2022 to that certain Joint Filing and Solicitation Agreement, dated March 11, 2022 (the “Agreement”), by and among Velan Capital Partners LP, Velan Capital Holdings LLC (“Velan GP”), Velan Capital Investment Management LP (“Velan Capital”), Avego Management, LLC (“Avego”), Balaji Venkataraman, Repertoire Master Fund LP, Repertoire Holdings LLC, Repertoire Partners LP, Repertoire Partners GP LLC, Deepak Sarpangal, Eric J. Ende, R. John Fletcher, Cynthia L. Flowers and Ann MacDougall (collectively, the “Existing Members”) and Velan Capital Management LLC (“Velan IM GP”) and Adam Morgan (together with Velan IM GP, the “New Members”).
May 17, 2023Support Agreement • May 19th, 2023 • Velan Capital Investment Management LP • Pharmaceutical preparations
The undersigned understands that Alimera Sciences, Inc., a Delaware corporation (“Company”), and certain investors, including the undersigned (the “Investors”), are entering into a Joinder and Amendment to Securities Purchase Agreement dated as of the date hereof (the “Amendment”), which amends that certain Securities Purchase Agreement dated as of March 24, 2023 (the “Securities Purchase Agreement”). All capitalized terms used in this letter agreement but not defined in this letter agreement shall have the meanings given such terms in the Securities Purchase Agreement, as amended. The undersigned is a stockholder of the Company and is entering into this letter agreement to induce the Company to enter into the Amendment and to consummate the transactions contemplated thereby.
JOINT FILING AGREEMENTJoint Filing Agreement • March 20th, 2023 • Velan Capital Investment Management LP • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.0001 per share, of Praxis Precision Medicines, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • March 7th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.0001 per share, of Radius Health, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
GROUP AGREEMENTGroup Agreement • March 7th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations
THIS AGREEMENT, dated as of February 15, 2022 (the “Effective Date”), is by and between Repertoire Partners LP (“Repertoire”) and Velan Capital Investment Management LP (“Velan”) (each, a “Party” and, collectively, the “Parties” or the “Group”).
SECOND AMENDMENT TO JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • May 25th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations
This Second Amendment (this “Second Amendment”) is made and entered into as of May 24, 2022 to that certain Joint Filing and Solicitation Agreement, dated March 11, 2022, as amended on April 18, 2022 (the “Agreement”), by and among Velan Capital Partners LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Velan Capital Management LLC, Adam Morgan, Balaji Venkataraman, Repertoire Master Fund LP, Repertoire Holdings LLC, Repertoire Partners LP, Repertoire Partners GP LLC, Deepak Sarpangal, Eric J. Ende, R. John Fletcher, Cynthia L. Flowers and Ann MacDougall.
JOINT FILING AGREEMENTJoint Filing Agreement • May 19th, 2023 • Velan Capital Investment Management LP • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Joint Filing AgreementJoint Filing Agreement • March 28th, 2024 • Velan Capital Investment Management LP • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on Schedule 13G dated March 28, 2024 with respect to the Common Stock, par value $0.01 per share, of Outlook Therapeutics, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
TERMINATION AGREEMENTTermination Agreement • July 12th, 2022 • Velan Capital Investment Management LP • Pharmaceutical preparations
Each of the undersigned is a party to that certain Joint Filing and Solicitation Agreement, dated as of March 11, 2022, as amended on April 18, 2022 and May 24, 2022 (as amended, the “Joint Filing and Solicitation Agreement”). In accordance with Section 10 of the Joint Filing and Solicitation Agreement, each of the undersigned hereby agrees that the Joint Filing and Solicitation Agreement is terminated effective immediately.
JOINT FILING AGREEMENTJoint Filing Agreement • March 31st, 2023 • Velan Capital Investment Management LP • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
